Segment & Geographic Data
Quant-Grade Normalized (live API)
API & CSV Delivery
Geron's Business Segments
Geron's reported revenue by business segment and by geographic region, quarterly and annual, normalized against the consolidated income statement. Free below: the top 3 rows per table, this quarter and this fiscal year. Subscriber access adds the full segment history and operating income by segment.
Segment Data As of Q1 FY2026
Reportable Segments
1
Largest Segment
Reportable
Total Revenue
$ 52
Regions Reported
-
Revenue Share by Reportable Segment - Q1 FY2026
- Reportable99.9%
Revenue by Reportable Segment - Q1 FY2026
| Segment | Revenue (Millions) | % of Total |
|---|---|---|
| Reportable | $ 52 | 99.9% |
Revenue by Product & Service Category - Q1 FY2026
- Revenues Before Adjustments0%
- Product99.9%
- Royalty0.1%
- Sales Returns and Allowance0%
- Government rebates0%
- Distributor service fees0%
- Chargebacks0%
- Total Gross to Net Adjustments0%
Revenue by Product & Service Category - Q1 FY2026
| Category | Revenue (Millions) | % of Total |
|---|---|---|
| Revenues Before Adjustments | $ 65 | - |
| Product | $ 52 | 99.9% |
| Royalty | $ 0 | 0.1% |
Product and service categories are a supplemental disclosure and are not required to sum to consolidated revenue or to the reportable segments above.
Description of Geron
Geron Corporation is a biotech company headquartered in Menlo Park, California, United States. The company focuses on the research and development of therapies to treat cancer and various degenerative disorders. They specialize in anti-telomerase therapy, which is aimed at preventing the uncontrolled multiplication of cells. This therapy targets an enzyme called telomerase, which is responsible for the unending replication of cancerous cells.
The company's flagship product, Imetelstat, is a potent inhibitor of telomerase that has shown promising results in the treatment of blood cancers such as myelodysplastic syndrome (MDS) and acute myeloid leukemia (AML). The drug works by disabling telomerase, a key enzyme that allows cancer cells to divide indefinitely. Imetelstat has been shown to prolong survival in patients with MDS and AML, with some patients achieving complete remission.
In addition to Imetelstat, Geron has an active pipeline of drugs in development for the treatment of cancer and degenerative diseases. These include GRN510, a drug that targets breast cancer stem cells, and GRNVAC1, a therapeutic vaccine for cancer.
Geron's research also extends to degenerative diseases such as spinal cord injuries, and it has a drug in development called GRNOPC1 that targets the regeneration of damaged nerve cells in the spinal cord. This therapy aims to replace damaged oligodendrocytes in the spinal cord, which help to protect and insulate nerve cells.
Since its inception in 1990, Geron has raised more than $1 billion in funding for research and development. The company collaborates with various partners from the pharmaceutical industry and academic institutions to advance its products and pursue new therapies.
Overall, Geron Corporation is a pioneering biotech company that continues to drive innovation in the areas of cancer and degenerative disease therapy. Its portfolio of products in development and research collaborations reflect its commitment to finding new treatments for some of the world's most challenging medical conditions.
The company's flagship product, Imetelstat, is a potent inhibitor of telomerase that has shown promising results in the treatment of blood cancers such as myelodysplastic syndrome (MDS) and acute myeloid leukemia (AML). The drug works by disabling telomerase, a key enzyme that allows cancer cells to divide indefinitely. Imetelstat has been shown to prolong survival in patients with MDS and AML, with some patients achieving complete remission.
In addition to Imetelstat, Geron has an active pipeline of drugs in development for the treatment of cancer and degenerative diseases. These include GRN510, a drug that targets breast cancer stem cells, and GRNVAC1, a therapeutic vaccine for cancer.
Geron's research also extends to degenerative diseases such as spinal cord injuries, and it has a drug in development called GRNOPC1 that targets the regeneration of damaged nerve cells in the spinal cord. This therapy aims to replace damaged oligodendrocytes in the spinal cord, which help to protect and insulate nerve cells.
Since its inception in 1990, Geron has raised more than $1 billion in funding for research and development. The company collaborates with various partners from the pharmaceutical industry and academic institutions to advance its products and pursue new therapies.
Overall, Geron Corporation is a pioneering biotech company that continues to drive innovation in the areas of cancer and degenerative disease therapy. Its portfolio of products in development and research collaborations reflect its commitment to finding new treatments for some of the world's most challenging medical conditions.
Geron Corporation is a clinical-stage biopharmaceutical company specializing in the development and commercialization of innovative therapies aimed at treating various cancers and chronic degenerative diseases. The company is committed to leveraging groundbreaking science and technology to create therapies that have the potential to significantly impact patient outcomes and enhance quality of life on a global scale.
Segments
Geron Corporation focuses primarily on a singular business segment: the development of therapeutic products targeting cancer and other degenerative diseases. Recognizing the rapid advancements in the field of regenerative medicine and immunotherapy, the company has expanded its focus to include cell-based therapies that offer promising avenues for treatment. This includes harnessing the body’s own immune system and regenerative capabilities to devise revolutionary treatments for complex health conditions.
Products
Geron Corporation has an active and diverse pipeline of product candidates, which include:
1. Imetelstat:
- Overview: Imetelstat is Gerons leading product candidate and represents its flagship offering aimed at addressing hematologic myeloid malignancies (HMMs).
- Mechanism: This therapy is a telomerase inhibitor designed to target and inhibit cancer cells characterized by high telomerase activity. By manipulating the telomerase enzyme, Imetelstat aims to induce apoptosis in malignant cells, thereby improving survival outcomes for patients suffering from conditions such as myelodysplastic syndromes (MDS) and acute myeloid leukemia (AML).
- Current Status: Ongoing Phase 2 clinical trials are underway to evaluate its efficacy and safety profile.
2. GRN510:
- Overview: Positioned as a potential cellular immunotherapy, GRN510 targets the treatment of solid-tumor cancers.
- Mechanism: This therapy utilizes autologous dendritic cells, which are modified to present tumor-associated antigens. By loading these cells with the patients own RNA, GRN510 is designed to initiate a strong immune response against tumor cells, potentially leading to improved tumor regression.
- Clinical Development: Current efforts are focused on advancing GRN510 through investigational clinical trials to assess its therapeutic potential in various solid tumor types.
3. GRN300:
- Overview: Designed for the treatment of osteoarthritis, GRN300 is an innovative cell therapy candidate that harnesses the bodys own regenerative capabilities.
- Mechanism: The therapy involves the use of modified adult mesenchymal stem cells (MSCs) that express human telomerase reverse transcriptase (TERT). This modification promotes cell proliferation and engages regenerative processes aimed at restoring cartilage integrity and function in osteoarthritis-affected joints.
- Target Population: By focusing on degenerative diseases, particularly osteoarthritis, Geron aims to address a significant market need for effective non-invasive therapies in the area of orthopedic care.
Services
In addition to product development, Geron Corporation offers an array of professional services designed to support and enhance the safe and effective use of its therapeutic portfolio, including:
1. Clinical Study Services:
- Geron provides robust support for clinical studies integral to evaluating the safety, efficacy, and overall performance of its therapeutic candidates. This involves close collaborations with hospitals, research clinics, and academic institutions to facilitate comprehensive clinical trials.
2. Regulatory Affairs Services:
- Understanding the complexities of regulatory compliance, Geron offers extensive support in navigating the intricate landscape of regulatory requirements impacting drug development and commercialization. The services encompass the preparation of extensive regulatory submissions, handling negotiations with relevant regulatory bodies, and ensuring full compliance with changing guidelines and requirements.
3. Commercialization Services:
- As products progress through clinical development, Geron enhances its commercialization strategy through offering detailed market research, product positioning initiatives, and the establishment of strategic partnerships. This service is critical for preparing the product for launch, securing market access, and achieving long-term commercial success.
Conclusion
Geron Corporation stands at the forefront of biopharmaceutical innovation, driven by a dedication to tackling complex medical challenges. Through its focused development of advanced therapeutic products, alongside a full suite of supportive services, Geron aims to make a meaningful impact in the realms of oncology and regenerative medicine. The companys commitment to research, clinical excellence, and strategic partnerships positions it well to fulfill its mission of improving patient outcomes on a global scale.
Segments
Geron Corporation focuses primarily on a singular business segment: the development of therapeutic products targeting cancer and other degenerative diseases. Recognizing the rapid advancements in the field of regenerative medicine and immunotherapy, the company has expanded its focus to include cell-based therapies that offer promising avenues for treatment. This includes harnessing the body’s own immune system and regenerative capabilities to devise revolutionary treatments for complex health conditions.
Products
Geron Corporation has an active and diverse pipeline of product candidates, which include:
1. Imetelstat:
- Overview: Imetelstat is Gerons leading product candidate and represents its flagship offering aimed at addressing hematologic myeloid malignancies (HMMs).
- Mechanism: This therapy is a telomerase inhibitor designed to target and inhibit cancer cells characterized by high telomerase activity. By manipulating the telomerase enzyme, Imetelstat aims to induce apoptosis in malignant cells, thereby improving survival outcomes for patients suffering from conditions such as myelodysplastic syndromes (MDS) and acute myeloid leukemia (AML).
- Current Status: Ongoing Phase 2 clinical trials are underway to evaluate its efficacy and safety profile.
2. GRN510:
- Overview: Positioned as a potential cellular immunotherapy, GRN510 targets the treatment of solid-tumor cancers.
- Mechanism: This therapy utilizes autologous dendritic cells, which are modified to present tumor-associated antigens. By loading these cells with the patients own RNA, GRN510 is designed to initiate a strong immune response against tumor cells, potentially leading to improved tumor regression.
- Clinical Development: Current efforts are focused on advancing GRN510 through investigational clinical trials to assess its therapeutic potential in various solid tumor types.
3. GRN300:
- Overview: Designed for the treatment of osteoarthritis, GRN300 is an innovative cell therapy candidate that harnesses the bodys own regenerative capabilities.
- Mechanism: The therapy involves the use of modified adult mesenchymal stem cells (MSCs) that express human telomerase reverse transcriptase (TERT). This modification promotes cell proliferation and engages regenerative processes aimed at restoring cartilage integrity and function in osteoarthritis-affected joints.
- Target Population: By focusing on degenerative diseases, particularly osteoarthritis, Geron aims to address a significant market need for effective non-invasive therapies in the area of orthopedic care.
Services
In addition to product development, Geron Corporation offers an array of professional services designed to support and enhance the safe and effective use of its therapeutic portfolio, including:
1. Clinical Study Services:
- Geron provides robust support for clinical studies integral to evaluating the safety, efficacy, and overall performance of its therapeutic candidates. This involves close collaborations with hospitals, research clinics, and academic institutions to facilitate comprehensive clinical trials.
2. Regulatory Affairs Services:
- Understanding the complexities of regulatory compliance, Geron offers extensive support in navigating the intricate landscape of regulatory requirements impacting drug development and commercialization. The services encompass the preparation of extensive regulatory submissions, handling negotiations with relevant regulatory bodies, and ensuring full compliance with changing guidelines and requirements.
3. Commercialization Services:
- As products progress through clinical development, Geron enhances its commercialization strategy through offering detailed market research, product positioning initiatives, and the establishment of strategic partnerships. This service is critical for preparing the product for launch, securing market access, and achieving long-term commercial success.
Conclusion
Geron Corporation stands at the forefront of biopharmaceutical innovation, driven by a dedication to tackling complex medical challenges. Through its focused development of advanced therapeutic products, alongside a full suite of supportive services, Geron aims to make a meaningful impact in the realms of oncology and regenerative medicine. The companys commitment to research, clinical excellence, and strategic partnerships positions it well to fulfill its mission of improving patient outcomes on a global scale.